Back to Search
Start Over
Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.
- Source :
-
American journal of physiology. Heart and circulatory physiology [Am J Physiol Heart Circ Physiol] 2015 May 01; Vol. 308 (9), pp. H1020-9. Date of Electronic Publication: 2015 Feb 27. - Publication Year :
- 2015
-
Abstract
- This study addressed the hypothesis that inhibiting the soluble epoxide hydrolase (sEH)-mediated degradation of epoxy-fatty acids, notably epoxyeicosatrienoic acids, has an additional impact against cardiovascular damage in insulin resistance, beyond its previously demonstrated beneficial effect on glucose homeostasis. The cardiovascular and metabolic effects of the sEH inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB; 10 mg/l in drinking water) were compared with those of the sulfonylurea glibenclamide (80 mg/l), both administered for 8 wk in FVB mice subjected to a high-fat diet (HFD; 60% fat) for 16 wk. Mice on control chow diet (10% fat) and nontreated HFD mice served as controls. Glibenclamide and t-AUCB similarly prevented the increased fasting glycemia in HFD mice, but only t-AUCB improved glucose tolerance and decreased gluconeogenesis, without modifying weight gain. Moreover, t-AUCB reduced adipose tissue inflammation, plasma free fatty acids, and LDL cholesterol and prevented hepatic steatosis. Furthermore, only the sEH inhibitor improved endothelium-dependent relaxations to acetylcholine, assessed by myography in isolated coronary arteries. This improvement was related to a restoration of epoxyeicosatrienoic acid and nitric oxide pathways, as shown by the increased inhibitory effects of the nitric oxide synthase and cytochrome P-450 epoxygenase inhibitors l-NA and MSPPOH on these relaxations. Moreover, t-AUCB decreased cardiac hypertrophy, fibrosis, and inflammation and improved diastolic function, as demonstrated by the increased E/A ratio (echocardiography) and decreased slope of the end-diastolic pressure-volume relation (invasive hemodynamics). These results demonstrate that sEH inhibition improves coronary endothelial function and prevents cardiac remodeling and diastolic dysfunction in obese insulin-resistant mice.<br /> (Copyright © 2015 the American Physiological Society.)
- Subjects :
- Animals
Blood Glucose drug effects
Blood Glucose metabolism
Coronary Vessels enzymology
Coronary Vessels physiopathology
Disease Models, Animal
Dose-Response Relationship, Drug
Eicosanoids metabolism
Endothelium, Vascular enzymology
Endothelium, Vascular physiopathology
Epoxide Hydrolases metabolism
Glyburide pharmacology
Heart Diseases enzymology
Heart Diseases etiology
Heart Diseases physiopathology
Hypoglycemic Agents pharmacology
Inflammation Mediators metabolism
Lipids blood
Male
Mice
Nitric Oxide metabolism
Obesity blood
Obesity complications
Obesity enzymology
Obesity physiopathology
Time Factors
Urea pharmacology
Vasodilator Agents pharmacology
Ventricular Function, Left drug effects
Ventricular Remodeling drug effects
Benzoates pharmacology
Coronary Vessels drug effects
Endothelium, Vascular drug effects
Enzyme Inhibitors pharmacology
Epoxide Hydrolases antagonists & inhibitors
Heart Diseases prevention & control
Insulin Resistance
Obesity drug therapy
Urea analogs & derivatives
Vasodilation drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1522-1539
- Volume :
- 308
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- American journal of physiology. Heart and circulatory physiology
- Publication Type :
- Academic Journal
- Accession number :
- 25724490
- Full Text :
- https://doi.org/10.1152/ajpheart.00465.2014